April 9, 2018 | Posted by Team in News |
PALO ALTO, Calif., April 9, 2018–Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with Ranomics to offer online access to its mutagenesis platform to scientists around the globe.
Ranomics is a Toronto-based biotechnology company whose mission is to enable transformative discoveries using genomics. The VariantFind™ platform offers unique mutagenesis services to build comprehensive variant libraries on complex and long DNA sequences, enabling its partners to make breakthrough discoveries.
“We are proud to team up with Science Exchange, a move that will give life sciences communities all over the world quick and easy access to quality science,” says Leo Wan, Ph.D., CEO and co-founder of Ranomics. “Our core strength has always been building cost-effective and diverse DNA libraries rapidly. Now we can effectively assist customers who want to use these libraries in high-throughput cell-based assays as part of a more full-service approach to pre-clinical research.”
“We are thrilled to partner with Ranomics to make its innovative gene mutagenesis services available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is always looking to add innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research services. Ranomics has impressed us with their superb progress in mutagenesis and cell-based screening.”
About Ranomics
Ranomics is a Toronto-based biotechnology company whose mission is to enable transformative discoveries using genomics. Ranomics’s proprietary functional genomics platform offers unparalleled ability to study genetic variations within the context of fundamental biology and drug discovery. The platform promotes unbiased and systematic characterization of gene variations, leading to the development of novel therapeutics in a derisked and cost-effective manner. The VariantFind™ technology is a key component of Ranomics’s functional genomics platform, and offers unprecedented scalability and flexibility in building DNA variant libraries. The VariantFind™ technology is used by partners to find meaningful variants in their research programs that will propel discovery and make better products. Ranomics is committed to providing top-quality variant libraries at competitive costs with quick turnaround time for all partners. Ranomics is an alumnus of IndieBio and graduate of JLabs Toronto.
Start finding target gene variations today! Request a quote at the Ranomics storefront:
March 19, 2018 | Posted by Team in News |
PALO ALTO, CA, March 6, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development services, announced a collaboration with PhenoSwitch Bioscience to offer online access to its mass spectrometry (LC-MS/MS) services, including SWATH™ proteomics offerings to scientists around the globe.
PhenoSwitch Bioscience is a Quebec, Canada-based contract research organization (CRO) whose mission is to help scientists elevate their research projects with innovative mass spectrometry solutions, in a collaborative manner.
“We are proud to team up with Science Exchange as we share similar philosophies: giving scientists quick and easy access to quality science,” says Hugo Gagnon, Ph.D., CEO and co-founder of PhenoSwitch Bioscience. “Our continuous internal mission to optimize our workflows, attentive listening to our client’s needs and careful scientific revisions are the keys to our success when offering complex services like LC-MS/MS and SWATH™ omics. Moreover, being a small, multidisciplinary scientific team allows us to be flexible and able to accommodate custom requests.”
“We are excited to collaborate with PhenoSwitch Bioscience to make its mass spectrometry services readily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is heartily committed to adding innovative and qualified providers to our platform, giving scientists quick access to a comprehensive selection of research services. PhenoSwitch Bioscience met our rigorous qualification criteria while demonstrating breakthrough discoveries in the field of drug development, biomarker discovery and fundamental science.”
About PhenoSwitch Bioscience
PhenoSwitch Bioscience Inc. was established in 2013 with the goal of providing expert services in mass spectrometry to major actors in the life science research industry. Today, PhenoSwitch uses the 20+ years of combined life science research experience of its Ph.D. level scientists to help solve research and/or drug discovery problems with modern mass spectrometry approaches. Our team’s commitment and in-depth understanding of mass spectrometry brought us among the world’s leaders in SWATH™ omics technology. We have also grown a unique expertise in the development of high sensitivity micro-flow LC-MS/MS methods. Apart from our proteomics, lipidomics and metabolomics services, we also offer several pre-developed targeted quantitative panels as well as custom methods development for small and large molecules bioanalysis in complex matrices. Follow the company on Twitter @PhenoSwitch.
Interested in learning more about PhenoSwitch Bioscience’s technologies? Request a quote to receive information:
March 12, 2018 | Posted by Team in News |
PALO ALTO, CA, March 12, 2018 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced a partnership with PhenoVista Biosciences to offer online access to its Phenotypic Assay Development Services to scientists around the globe.
“Science Exchange has been a steadfast ally of ours since we founded PhenoVista back in 2014. They have always understood the strength of our quantitative imaging-based approach and immediately recognized the great strides our scientists make to deliver the highest quality data possible. We’re very excited about taking our relationship with Science Exchange to the next level and look forward to working with new groups of scientists across the globe.” says James G. Evans, Ph.D., CEO and Founder of PhenoVista Biosciences. PhenoVista Biosciences is a San Diego, California-based CRO and is the leading provider of custom phenotypic assay services. The company’s mission is to enrich the drug discovery community with high-quality information derived from physiologically relevant cell models. PhenoVista specializes in custom assay development in a wide range of therapeutic areas, including CNS, immuno-oncology, and rare diseases.
“We’re delighted to strengthen our partnership with PhenoVista to ensure that their cutting-edge assay services can be made more easily available to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified providers to our platform, so scientists have the secure services they need readily available to aid their discoveries. PhenoVista met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of phenotypic assays.”
About PhenoVista Biosciences
PhenoVista is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically-driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. A key advantage that PhenoVista leverages is the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems, with cutting-edge quantitative imaging to deliver clear, actionable output data. PhenoVista’s clients include the majority of top-20 pharmaceutical companies as well as numerous VC-funded biotechnology start-ups. PhenoVista was founded by Dr. James G. Evans and Dr. Anthony Essex in 2014. A privately funded and revenue-driven company, PhenoVista continues to see double-digit revenue growth year over year.
Connect with the PhenoVista team by requesting a quote on their storefront today!
February 28, 2018 | Posted by Team in News |
PALO ALTO, CA, February 28, 2018 – Science Exchange, the world’s leading platform for outsourced research and development (R&D) services, announced a partnership with Likarda to offer online access to its innovative 3D compound screening and assay development services to scientists around the globe.
Likarda is a Kansas City-based contract research organization (CRO) and a leading provider of drug discovery and development services, primarily using 3D cell-based assaying technologies and microencapsulation. The company’s mission is to combine comprehensive early-phase discovery research with consultative and analytical services so that those in the drug discovery process can move forward confidently, efficiently, and affordably.
“We focus on bringing to market disruptive technologies that improve healthcare outcomes and lower costs for pets and people alike. To illustrate, our proprietary three-dimensional cell culture system serves as a predictive model to demonstrate how test drug compounds work in the human body. Partnering with Science Exchange gives its global client base the fastest path to our novel technologies and services,” stated Karthik Ramachandran, Ph.D., Likarda’s vice president and co-founder.
“We are excited to team up with Likarda to make its drug screening and assay development services accessible to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists can securely and readily access the services they need to aid their discoveries. Likarda met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of 3D cell-based assaying technologies and microencapsulation.”
About Likarda
Founded in 2012, Likarda LLC is a world-class, cutting-edge biotech research laboratory for science entrepreneurs, pharmaceutical and nutraceutical companies, animal health, and contract research organizations (CRO). We focus on bringing to market disruptive technologies that improve health-care outcomes and lower costs for pets and people alike. Follow the CRO on Twitter @likardallc.
Interested in trying out Likarda’s technologies for your project?
Request a quote from the Likarda team
February 12, 2018 | Posted by Team in News |
Palo Alto, CA – February 12, 2018 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic collaboration with Venture Catalyst, a unit within the Technology Management and Corporate Relations division of the UC Davis Office of Research which supports the development of new ventures fueled by university research.
Science Exchange will provide entrepreneurs and startups participating in the Venture Catalyst Smart Toolkit for Accelerated Research Translation (START™) Program immediate access to the private R&D marketplace with dedicated PhD-level sourcing support around the clock and a special contracting structure to accelerate their research and development projects.
“The Science Exchange platform solves the challenges of R&D outsourcing by providing scientists with on-demand access to a diverse network of prequalified external providers under a single relationship while also providing sourcing departments with more information and control over their outsourcing spending,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be collaborating with Venture Catalyst to offer a customized R&D marketplace and help its portfolio of companies complete their research and clinical projects more quickly and efficiently. It’s clear that Venture Catalyst is supporting companies with extremely promising technologies in development, and we’re honored to help get their discoveries to market faster.”
With this collaboration, Science Exchange will support client-specific governance, approval workflows, and preferred vendors, all the while enabling instant access to research services and custom products from 2,500 providers in over 6,000 research areas. To help external service providers minimize the risk frequently associated with outsourcing, Science Exchange’s guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by the best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated outsourced work.
Venture Catalyst is the latest innovation and startup support organization to choose to partner with Science Exchange. They now join more than 30 enterprise organizations including most of the top 20 biopharma companies that use Science Exchange to more efficiently manage outsourced R&D.
“Science Exchange offers a unique platform for our startups to connect with a broad network of qualified scientific providers,” said Dushyant Pathak, Associate Vice Chancellor of Research and Executive Director of Venture Catalyst at UC Davis. “We anticipate that working with Science Exchange through the START Program will enable us to commercially advance the discoveries made by Venture Catalyst-supported startups and early-stage companies, in areas as diverse as biomedical and life sciences, agriculture and animal health, and physical sciences and engineering.”
About Venture Catalyst
Venture Catalyst furthers the University’s educational, research and public mission by supporting UC Davis students, faculty and researchers in translating science, engineering and innovative research through well-resourced startups, into societal impact. Venture Catalyst engages collaboratively with internal and external drivers of innovation and works closely with the University’s Institute for Innovation & Entrepreneurship. In addition to its Smart Toolkit for Accelerated Research Translation (START™) program, Science Translation and Innovative Research (STAIR™) Proof-of-Concept grants, Venture Catalyst supports a network of regional technology startup incubators through its Distributed Research Incubation & Venture Engine (DRIVE™) Network.
December 18, 2017 | Posted by Team in News |
Palo Alto, CA – December 18, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced a strategic partnership with Breakout Labs, a fund within the Thiel Foundation that backs scientist-entrepreneurs working at the intersections of technology, biology, materials, and energy. The newly formed partnership allows for Breakout Labs to provide its portfolio companies’ scientists with on-demand access to a global network of research suppliers via the Science Exchange-powered private marketplace.
The private marketplace enables instant access to thousands of research tools, technologies, and services from over 2,500+ commercial CROs, academic labs, and government facilities under a single Science Exchange contract. Additionally, the platform users receive end-to-end PhD-level support from the Science Exchange staff scientists in identifying the best external innovations to expedite their R&D cycles.
“Our companies are small innovative startups that, despite being cash-constrained, are at the forefront of radical scientific breakthroughs,” said Hemai Parthasarathy, Scientific Director of Breakout Labs. “Science Exchange’s marketplace helps these companies adopt virtualization in their R&D process and give them an opportunity to access external resources they need to bring their innovations to market. Science Exchange fits into the ethos that prompted the formation of Breakout Labs by removing barriers for startups to access scientific services that will help accelerate their discoveries.”
“At Science Exchange, we are passionate about accelerating discovery by making connections — in this case, vital connections between scientist-entrepreneurs and experienced providers of scientific products and services,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Through this partnership, the scientists at Breakout Labs’ companies, can now focus on what they do best, bringing game-changing scientific discoveries to market, and rely on us to find the best scientific providers to help them accomplish that.”
Breakout Labs is the latest R&D organization to choose to partner with Science Exchange and join more than 30 enterprise clients and Life Science incubators that are effectively managing their outsourced R&D with Science Exchange-powered marketplaces.
About Breakout Labs
Breakout Labs is a revolving fund within the Thiel Foundation that supports early stage companies as they transition radical scientific advances out of the research lab and into the economy. The program backs bold scientists who work at the intersections of technology, biology, materials, and energy. More than capital, Breakout Labs provides additional support through a two-year program that includes introductions to follow-on funders, corporate partners and other resources to drive commercialization. To learn more, visit: www.breakoutlabs.org.
December 11, 2017 | Posted by Team in News |
PALO ALTO, CA, December 11, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced the partnership with Bioinformatics Solutions, Inc. to offer online access to its protein de novo sequencing services to scientists around the globe.
As the creators of the well-known, highly established PEAKS Software, the golden standard of de novo sequencing, Bioinformatics Solutions, Inc., offers their de novo sequencing expertise to scientists at a new level by sequencing the samples themselves.
“Bioinformatics Solutions, Inc. has developed a proprietary de novo protein sequencing workflow to retrieve the amino acid sequence of an unknown antibody protein with state-of-the-art mass spectrometry techniques. Through this workflow, the sequence assembly is purely based on de novo sequencing. Therefore, no database, cDNA, mRNA, or hybridoma cell line is required,” exclaims Baozhen Shan, CEO of Bioinformatics Solutions, Inc. “With constant ongoing research at Bioinformatics Solutions, Inc., the advanced technology will ensure our service delivers a highly accurate sequence, identification of sequence variants, glycosylations, and unknown modifications. By partnering with Science Exchange, these sequencing services will now be available to researchers all over the world to help them make breakthrough discoveries.”
Over the last few years, Science Exchange has undergone extensive growth and recently received a $28 million in Series C funding led by Norwest Venture Partners. By continuing to team up with companies like Bioinformatics Solutions, Inc. Science Exchange is providing researchers worldwide with access to the most important scientific services to advance their experiments.
“We are excited to partner with Bioinformatics Solutions, Inc. to make available its protein de novo sequencing services to scientists worldwide,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Science Exchange is committed to adding the most innovative and qualified service providers to our platform, so scientists have the services they need securely and readily available to aid their discoveries. Bioinformatics Solutions, Inc. met our rigorous standards for quality and compliance while demonstrating breakthrough discoveries in the field of proteomics analysis.”
About Bioinformatics Solutions, Inc.
For more than 15 years, Bioinformatics Solutions, Inc. has been changing the field of proteomics analysis, by pushing the boundaries of its computational limits and striving to provide groundbreaking research with the customer-first approach. Bioinformatics Solutions, Inc. believes the only solution is one that incorporates quality and timely results, a satisfying product experience, customer support and two-way communication. This diverse and adaptable group is committed to serving the needs of pharmaceutical, biotechnological, and academic scientists; and to the progression of recombinant protein production and drug discovery research. For more information, visit www.scienceexchange.com/labs/bioinformatics-solutions-inc. Follow the company on Twitter @PEAKSProteomics and @PEAKSAB.
November 21, 2017 | Posted by Team in News |
Dr. Elizabeth Iorns Honored as Female Entrepreneur of the Year and Science Exchange as Most Innovative Company of the Year
Palo Alto, CA – November 21, 2017 — Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D), today announced that CEO and Co-Founder Dr. Elizabeth Iorns, has been named the winner of the Gold Stevie® Award for Female Entrepreneur of the Year. In addition, Science Exchange has been named Most Innovative Company of the Year at the 14th annual Stevie Awards for Women in Business.
The Stevie Awards for Women in Business are the world’s top honors for female entrepreneurs, executives, employees and the organizations they run. The 2017 awards received over 1500 entries from 25 nations and territories; winners were recognized at a November 17 event in New York City.
Dr. Elizabeth Iorns founded Science Exchange in 2011 and has built a global company that has raised over $58M in venture funding. Dr. Iorns has led Science Exchange to rapid growth with enterprise partnerships with the most innovative R&D focused Fortune 100 companies. Science Exchange provides a technology platform for efficient access to the world’s best external R&D partners. Through Science Exchange, scientists can instantly connect and order outsourced scientific projects from over 2,500 top research facilities available under the Science Exchange contract.
“I am honored to receive the Stevie award and be recognized among other inspiring women and companies around the world,” said Dr. Elizabeth Iorns, co-founder and CEO of Science Exchange. “I am also extremely proud of the teams at Science Exchange that work tirelessly with our clients on their outsourced R&D projects to accelerate scientific discovery.”
“The judges were so impressed with the accomplishments of all of the Stevie Award-winning women and organizations. The 2017 Stevie Awards for Women in Business received a record number of nominations and had a record number of ceremony attendees,” said Michael Gallagher, founder and president of the Stevie Awards. “We congratulate all of this year’s Grand, Gold, Silver and Bronze Stevie Award winners for their achievements.”
Details about the Stevie Awards for Women in Business and the list of Stevie Award winners are available at www.StevieAwards.com/Women.
November 20, 2017 | Posted by Team in News |
PALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.
“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”
The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.
Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.
“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”
Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.
Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!
November 15, 2017 | Posted by Team in News |
PALO ALTO, CA, November 15, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research and development (R&D) services, announced today that Elizabeth Iorns, Ph.D., CEO of Science Exchange, has been elected to serve her first term on the Board of Directors of the Drug, Chemical & Associated Technologies Association (DCAT) beginning November 1, 2017. Members of DCAT’s Board of Directors are charged with the important work of guiding the organization’s strategic initiatives and activities.
“We are delighted to have Dr. Iorns join the Board of Directors,” said DCAT Executive Director Margaret Timony. “She brings a unique mix of leadership experiences that will add a valuable perspective to the board.”
“I am honored to join the board and work together with this great team to address key initiatives related to the pharmaceutical industry,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “Our mission at Science Exchange is to help accelerate innovation and scientific discoveries, and as a scientist myself, I feel joining DCAT’s board is a perfect opportunity for me to share my ideas and insights to support and advance its programs and services.”
About DCAT
The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.
Explore Science Exchange’s network of qualified service providers for:
Follow Us